Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Raymond

Showing results (51-60 of 173) with videos related to

Pageof 18
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|July 20, 2010
Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical developmentMarie-Paule Sablin, Chantal Dreyer, Camelia Colichi, et al.
Journal of Insurance Medicine (New York, N.Y.)|September 19, 2023
Methods for Inclusive Underwriting of Breast Cancer Risk with Machine Learning and Innovative AlgorithmsManuel Plisson, Antoine Moll, Valentine Sarrazin, et al.
Journal of Hepatology|December 15, 2010
Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinomaHélène Marijon, Safi Dokmak, Valérie Paradis, et al.
Journal of Insurance Medicine (New York, N.Y.)|September 18, 2025
Prostate Cancer Insurability: Population Identification Within the Insurability Corridor and the Right to be ForgottenAntoine Moll, Eric Raymond, Théo Schneider, et al.
Cancer Chemotherapy and Pharmacology|December 7, 2014
Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumorsDaniel Castellano, Enrique Grande, Juan Valle, et al.
American Journal of Translational Research|July 31, 2014
Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesisIsmael Ghanem, Maria E Riveiro, Valerie Paradis, et al.
Investigational New Drugs|September 19, 2007
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumorsCatherine Delbaldo, Eric Raymond, Karina Vera, et al.
Pharmacology & Therapeutics|December 3, 2014
Targeting the TGFβ pathway for cancer therapyCindy Neuzillet, Annemilaï Tijeras-Raballand, Romain Cohen, et al.
International Journal of Oncology|July 16, 2002
Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cellsEric Raymond, Christophe Louvet, Christophe Tournigand, et al.
World Journal of Gastroenterology|September 24, 2011
Gemcitabine in elderly patients with advanced pancreatic cancerOlivia Hentic, Chantal Dreyer, Vinciane Rebours, et al.
Pageof 18

Showing results (51-60 of 173) with videos related to

Sort By:
Pageof 18
Expert Opinion on Drug Metabolism & Toxicology|July 20, 2010
Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical developmentMarie-Paule Sablin, Chantal Dreyer, Camelia Colichi, et al.
Journal of Insurance Medicine (New York, N.Y.)|September 19, 2023
Methods for Inclusive Underwriting of Breast Cancer Risk with Machine Learning and Innovative AlgorithmsManuel Plisson, Antoine Moll, Valentine Sarrazin, et al.
Journal of Hepatology|December 15, 2010
Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinomaHélène Marijon, Safi Dokmak, Valérie Paradis, et al.
Journal of Insurance Medicine (New York, N.Y.)|September 18, 2025
Prostate Cancer Insurability: Population Identification Within the Insurability Corridor and the Right to be ForgottenAntoine Moll, Eric Raymond, Théo Schneider, et al.
Cancer Chemotherapy and Pharmacology|December 7, 2014
Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumorsDaniel Castellano, Enrique Grande, Juan Valle, et al.
American Journal of Translational Research|July 31, 2014
Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesisIsmael Ghanem, Maria E Riveiro, Valerie Paradis, et al.
Investigational New Drugs|September 19, 2007
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumorsCatherine Delbaldo, Eric Raymond, Karina Vera, et al.
Pharmacology & Therapeutics|December 3, 2014
Targeting the TGFβ pathway for cancer therapyCindy Neuzillet, Annemilaï Tijeras-Raballand, Romain Cohen, et al.
International Journal of Oncology|July 16, 2002
Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cellsEric Raymond, Christophe Louvet, Christophe Tournigand, et al.
World Journal of Gastroenterology|September 24, 2011
Gemcitabine in elderly patients with advanced pancreatic cancerOlivia Hentic, Chantal Dreyer, Vinciane Rebours, et al.
Pageof 18